Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ceramide Metabolism and Parkinson’s Disease—Therapeutic Targets
Antía Custodia, Marta Aramburu-Núñez, Clara Correa‐Paz, et al.
Biomolecules (2021) Vol. 11, Iss. 7, pp. 945-945
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Sphingolipids in neurodegenerative diseases
Xueyang Pan, Debdeep Dutta, Shenzhao Lu, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 24
More than meets the eye in Parkinson’s disease and other synucleinopathies: from proteinopathy to lipidopathy
Manuel Flores‐León, Tiago F. Outeiro
Acta Neuropathologica (2023) Vol. 146, Iss. 3, pp. 369-385
Open Access | Times Cited: 24
Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches
Zeba Firdaus, Xiaogang Li
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2320-2320
Open Access | Times Cited: 11
The relevance between abnormally elevated serum ceramide and cognitive impairment in Alzheimer’s disease model mice and its mechanism
Xin Liu, Yongzeng Jin, Xinyi Cheng, et al.
Psychopharmacology (2024) Vol. 241, Iss. 3, pp. 525-542
Closed Access | Times Cited: 9
Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders
Marzena Kurzawa‐Akanbi, Seshu R. Tammireddy, Ivo Fabrik, et al.
Acta Neuropathologica (2021) Vol. 142, Iss. 6, pp. 961-984
Open Access | Times Cited: 42
SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia
Siddharth Srivastava, Hagar Mor Shaked, Kenneth Gable, et al.
Brain (2023) Vol. 146, Iss. 4, pp. 1420-1435
Open Access | Times Cited: 17
Ceramide in cerebrovascular diseases
Huiqi Yuan, Bin Zhu, Cao Li, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 17
Fabry disease: Mechanism and therapeutics strategies
Xi Li, Xiangyi Ren, Yabing Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 26
'Fly-ing' from rare to common neurodegenerative disease mechanisms
Mengqi Ma, Matthew J. Moulton, Shenzhao Lu, et al.
Trends in Genetics (2022) Vol. 38, Iss. 9, pp. 972-984
Open Access | Times Cited: 24
Peripheral Upregulation of Parkinson’s Disease-Associated Genes Encoding α-Synuclein, β-Glucocerebrosidase, and Ceramide Glucosyltransferase in Major Depression
Razvan-Marius Brazdis, Claudia von Zimmermann, Bernd Lenz, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3219-3219
Open Access | Times Cited: 5
Plasma Ceramides Pathophysiology, Measurements, Challenges, and Opportunities
Melania Gaggini, Alessandro Pingitore, Cristina Vassalle
Metabolites (2021) Vol. 11, Iss. 11, pp. 719-719
Open Access | Times Cited: 31
From Lysosomal Storage Disorders to Parkinson’s Disease – Challenges and Opportunities
Rebecca Mächtel, Fanni Annamária Boros, Jan Philipp Dobert, et al.
Journal of Molecular Biology (2022) Vol. 435, Iss. 12, pp. 167932-167932
Open Access | Times Cited: 21
A Machine Learning Approach to Parkinson’s Disease Blood Transcriptomics
Ester Pantaleo, A. Monaco, Nicola Amoroso, et al.
Genes (2022) Vol. 13, Iss. 5, pp. 727-727
Open Access | Times Cited: 19
Integrated transcriptomics, proteomics and metabolomics to identify biomarkers of astragaloside IV against cerebral ischemic injury in rats
Xiaoyu Wei, Yu He, Haitong Wan, et al.
Food & Function (2023) Vol. 14, Iss. 8, pp. 3588-3599
Closed Access | Times Cited: 12
Untargeted Lipidomic Reveals Potential Biomarkers in Plasma Samples for the Discrimination of Patients Affected by Parkinson’s Disease
Kateryna Tkachenko, J.M. González-Sáiz, C. Pizarro
Molecules (2025) Vol. 30, Iss. 4, pp. 850-850
Open Access
Imipramine, an Acid Sphingomyelinase Inhibitor, Promotes Newborn Neuron Survival in the Hippocampus After Seizure
Song Hee Lee, Hyun Wook Yang, Beom Seok Kang, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 281-281
Open Access
Emerging roles of the acid sphingomyelinase/ceramide pathway in metabolic and cardiovascular diseases: Mechanistic insights and therapeutic implications
Hong-Ni Wang, Ye Wang, Siyao Zhang, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 2
Open Access
Cerebrospinal ceramides and cognition as a function of striatal asymmetry in early stage of Parkinson's disease
Anthony Nuber‐Champier, Philippe Voruz, Ioana Medeleine Constantin, et al.
Journal of Parkinson s Disease (2025)
Open Access
Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer’s Disease and Other Neurodegenerative Diseases
Antía Custodia, Daniel Romaus‐Sanjurjo, Marta Aramburu-Núñez, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8082-8082
Open Access | Times Cited: 16
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease
Manoj Kumar, Manasa P. Srikanth, Michela Deleidi, et al.
Human Molecular Genetics (2023) Vol. 32, Iss. 11, pp. 1888-1900
Open Access | Times Cited: 10
A defect in mitochondrial fatty acid synthesis impairs iron metabolism and causes elevated ceramide levels
Debdeep Dutta, Oguz Kanca, Seul Kee Byeon, et al.
Nature Metabolism (2023) Vol. 5, Iss. 9, pp. 1595-1614
Open Access | Times Cited: 10
Ceramide Metabolism Enzymes—Therapeutic Targets against Cancer
Ana Gómez-Larrauri, Upasana Das Adhikari, Marta Aramburu-Núñez, et al.
Medicina (2021) Vol. 57, Iss. 7, pp. 729-729
Open Access | Times Cited: 22
Involvement of Ceramide Metabolism in Cerebral Ischemia
Alberto Ouro, Clara Correa‐Paz, Elena Maqueda, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 15
The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism
Melissa R. Pitman, Alexander C. Lewis, Lorena T. Davies, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 13
Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease
Aaron W. Beger, Beatrix Dudzik, Randall L. Woltjer, et al.
Metabolites (2022) Vol. 12, Iss. 2, pp. 187-187
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top